Ocugen Secures $115M in Convertible Notes to Repay Debt, Fund Operations
Event summary
- Ocugen priced $115M of 6.75% convertible senior notes due 2034, with an option for an additional $15M.
- Net proceeds of ~$99.5M (or ~$112.6M with option exercised) will repay $32.7M in debt to Avenue Capital Group and fund general corporate purposes.
- Notes bear interest at 6.75% payable semi-annually, with conversion at ~$2.68 per share (45% premium to last traded price).
- Initial purchaser option exercisable within 13 days; closing expected May 7, 2026.
The big picture
Ocugen's $115M convertible note offering underscores its strategic pivot to strengthen its balance sheet amid biotech sector volatility. The move to repay high-cost debt and secure flexible funding reflects broader industry trends of financial restructuring to navigate uncertain market conditions. The conversion premium suggests confidence in future stock performance, but execution risks remain.
What we're watching
- Debt Management
- Whether Ocugen can sustain its debt obligations while maintaining operational flexibility.
- Stock Performance
- How the convertible notes' conversion premium and market conditions will impact Ocugen's share price.
- Funding Strategy
- The pace at which Ocugen deploys the remaining proceeds for growth initiatives.
Related topics